AMRN
AmarinCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
Vascepa sales stabilize, margins expand and legal/regulatory overhangs ease, restoring analyst confidence and lifting the stock above the anchor toward the bull target.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +14.2.
What can break
Adverse litigation or patent rulings
Momentum
55
Value
41
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.82 · Bull $20.57 · Bear $11.07
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-11 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $12.00
Why
Momentum55 · Δ7d +14.2
Value41 · Δ7d +0.0
Sentiment56 · Δ7d -1.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
55
34% active weight
Current posture
7d trendImproving
Δ7d
+14.2
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
56
33% active weight
Current posture
7d trendSoftening
Δ7d
-1.4
Δ21d
-
Why this grade
Composite grade C. Momentum 55.1 / Value 41.1 / Sentiment 55.8
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$303.58M
Beta
0.84
Shares Out
20.58M
P/E (TTM) · Derived
-7.9
P/S (TTM)
1.24
P/FCF (TTM) · Derived
-4.03
Rev YoY
+17.4%
EPS YoY
+98.5%
Gross Margin
+55.0%
Op Margin
-42.5%
Net Debt
-$294.22M
Current Ratio
3.45
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology